Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Cancer Res. 2019 Apr 1;79(7):1558-1572. doi: 10.1158/0008-5472.CAN-18-1858. Epub 2019 Feb 1.
Metastasis via the lymphatic vasculature is an important step in cancer progression. The formation of new lymphatic vessels (lymphangiogenesis), or remodeling of existing lymphatics, is thought to facilitate the entry and transport of tumor cells into lymphatic vessels and on to distant organs. The migration of lymphatic endothelial cells (LEC) toward guidance cues is critical for lymphangiogenesis. While chemokines are known to provide directional navigation for migrating immune cells, their role in mediating LEC migration during tumor-associated lymphangiogenesis is not well defined. Here, we undertook gene profiling studies to identify chemokine-chemokine receptor pairs that are involved in tumor lymphangiogenesis associated with lymph node metastasis. CCL27 and CCL28 were expressed in tumor cells with metastatic potential, while their cognate receptor, CCR10, was expressed by LECs and upregulated by the lymphangiogenic growth factor VEGFD and the proinflammatory cytokine TNFα. Migration assays demonstrated that LECs are attracted to both CCL27 and CCL28 in a CCR10-dependent manner, while abnormal lymphatic vessel patterning in CCR10-deficient mice confirmed the significant role of CCR10 in lymphatic patterning. analyses showed that LECs are recruited to a CCL27 or CCL28 source, while VEGFD was required in combination with these chemokines to enable formation of coherent lymphatic vessels. Moreover, tumor xenograft experiments demonstrated that even though CCL27 expression by tumors enhanced LEC recruitment, the ability to metastasize was dependent on the expression of VEGFD. These studies demonstrate that CCL27 and CCL28 signaling through CCR10 may cooperate with inflammatory mediators and VEGFD during tumor lymphangiogenesis. SIGNIFICANCE: The study shows that the remodeling of lymphatic vessels in cancer is influenced by CCL27 and CCL28 chemokines, which may provide a future target to modulate metastatic spread.
淋巴道转移是癌症进展的重要步骤。新淋巴管的形成(淋巴管生成)或现有淋巴管的重塑,被认为有利于肿瘤细胞进入淋巴管并转移到远处器官。淋巴管内皮细胞(LEC)向趋化因子迁移对于淋巴管生成至关重要。虽然趋化因子被认为为迁移免疫细胞提供了定向导航,但它们在介导肿瘤相关淋巴管生成过程中 LEC 迁移中的作用尚未明确。在这里,我们进行了基因谱研究,以确定参与与淋巴结转移相关的肿瘤淋巴管生成的趋化因子-趋化因子受体对。具有转移潜力的肿瘤细胞表达 CCL27 和 CCL28,而其同源受体 CCR10 则由 LEC 表达,并受淋巴管生成生长因子 VEGFD 和促炎细胞因子 TNFα 上调。迁移实验表明,LEC 以 CCR10 依赖的方式被吸引到 CCL27 和 CCL28 上,而 CCR10 缺陷小鼠的异常淋巴管模式证实了 CCR10 在淋巴管模式形成中的重要作用。 分析表明,LEC 被招募到 CCL27 或 CCL28 来源处,而 VEGFD 与这些趋化因子一起需要才能形成连贯的淋巴管。此外,肿瘤异种移植实验表明,尽管肿瘤中 CCL27 的表达增强了 LEC 的募集,但转移能力取决于 VEGFD 的表达。这些研究表明,CCL27 和 CCL28 通过 CCR10 的信号传导可能与炎症介质和 VEGFD 合作,参与肿瘤淋巴管生成。 意义:该研究表明,癌症中淋巴管的重塑受 CCL27 和 CCL28 趋化因子的影响,这可能为调节转移性扩散提供未来的目标。